tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Silexion Therapeutics Announces Reverse Share Split Plan

Story Highlights
  • Silexion Therapeutics announced a 1-for-15 reverse share split effective July 28, 2025.
  • The reverse split aims to enhance market position and support strategic growth initiatives.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Silexion Therapeutics Announces Reverse Share Split Plan

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Silexion Therapeutics ( (SLXN) ) is now available.

On July 16, 2025, Silexion Therapeutics announced a 1-for-15 reverse share split of its ordinary shares, effective after market close on July 28, 2025, to begin trading on a split-adjusted basis on July 29, 2025. This move aims to help Silexion comply with Nasdaq requirements, enhance its market position, and support strategic growth initiatives, reflecting the company’s commitment to maintaining its Nasdaq listing and advancing its RNAi therapeutics.

The most recent analyst rating on (SLXN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.

To see Spark’s full report on SLXN stock, click here.

More about Silexion Therapeutics

Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, a common oncogenic driver in human cancers. The company is advancing its first-generation product, LODER™, and its next-generation siRNA candidate, SIL204, which targets a broader range of KRAS mutations.

Average Trading Volume: 1,861,554

Technical Sentiment Signal: Sell

Current Market Cap: $6.77M

Find detailed analytics on SLXN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1